BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current Cancer Drug Targets

• Publication date

  2014-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1568009614666140121150930PMID 24446739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies.

  2016cited by this paper
• BRAF inhibitors: From the laboratory to clinical trials.

  2014cited by this paper
• Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

  2013cited by this paper
• Deja Vu: EGF receptors drive resistance to BRAF inhibitors.

  2013influential reference
• C-RAF mutations confer resistance to RAF inhibitors.

  2013influential reference
• B-Raf mutation: a key player in molecular biology of cancer.

  2013cited by this paper
• First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

  2013cited by this paper
• Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

  2013cited by this paper
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

  2013cited by this paper
• Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.

  2013cited by this paper
• Clinicopathological relevance of BRAF mutations in human cancer

  2013cited by this paper
• Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.

  2013cited by this paper
• Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

  2013cited by this paper
• Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.

  2013influential reference
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012influential reference
• Small molecule inhibitors of BRAF in clinical trials.

  2012cited by this paper
• Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

  2012cited by this paper
• The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012influential reference
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

  2012influential reference
• The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.

  2012influential reference
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

  2012influential reference
• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

  2012influential reference
• Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Dabrafenib and its potential for the treatment of metastatic melanoma

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

  2012cited by this paper
• miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

  2012cited by this paper
• Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

  2011cited by this paper
• In vivo Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein

  2011cited by this paper
• BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

  2011influential reference
• miR-22 represses cancer progression by inducing cellular senescence

  2011cited by this paper
• Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

  2011cited by this paper
• BRAF targeted therapy changes the treatment paradigm in melanoma

  2011cited by this paper
• BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

  2011cited by this paper
• Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

  2011cited by this paper
• Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

  2011cited by this paper
• Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

  2011cited by this paper
• RNA Interference and Cancer Therapy

  2011influential reference
• Current progress of siRNA/shRNA therapeutics in clinical trials

  2011cited by this paper
• Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.

  2011cited by this paper
• Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).

  2011cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010influential reference
• Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.

  2010cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• Dual-targeting siRNAs.

  2010cited by this paper
• Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling.

  2010cited by this paper
• Identification of miR-34a as a potent inhibitor of prostate cancer progenitor cells and metastasis by directly repressing CD44

  2010cited by this paper
• Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model

  2010cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

  2010cited by this paper
• Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference

  2010cited by this paper
• RAF protein-serine/threonine kinases: structure and regulation.

  2010cited by this paper
• The widespread regulation of microRNA biogenesis, function and decay

  2010cited by this paper
• Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

  2010cited by this paper
• MicroRNA control in the immune system: basic principles.

  2009cited by this paper
• Uncovering Growth-Suppressive MicroRNAs in Lung Cancer

  2009cited by this paper
• siRNA vs. shRNA: similarities and differences.

  2009cited by this paper
• MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.

  2009cited by this paper
• MEK1 mutations confer resistance to MEK and B-RAF inhibition

  2009cited by this paper
• microRNAs and the immune response

  2009influential reference
• Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.

  2009cited by this paper
• Suppression of non-small cell lung tumor development by the let-7 microRNA family

  2008cited by this paper
• Small non-coding RNAs in animal development

  2008cited by this paper
• MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation

  2008cited by this paper
• The noncoding RNA, miR‐126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3‐kinase signaling and is frequently lost in colon cancers

  2008cited by this paper
• Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

  2008influential reference
• miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells

  2008cited by this paper
• microRNAs and the immune response.

  2008cited by this paper
• Piecing Together the Mosaic of Early Mammalian Development through MicroRNAs*

  2008cited by this paper
• The let-7 microRNA reduces tumor growth in mouse models of lung cancer

  2008cited by this paper
• Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

  2008influential reference
• Control of cell proliferation pathways by microRNAs

  2008cited by this paper
• miRNAs: Little known mediators of oncogenesis.

  2008cited by this paper
• An Analysis of Human MicroRNA and Disease Associations

  2008cited by this paper
• Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Targeting microRNA expression to regulate angiogenesis.

  2008cited by this paper
• Clinicopathological features of CpG island methylator phenotype‐positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Endogenous human microRNAs that suppress breast cancer metastasis

  2008cited by this paper
• A developmental view of microRNA function.

  2007cited by this paper
• Small RNAs, big potential: the role of MicroRNAs in stem cell function.

  2007cited by this paper
• Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways.

  2007cited by this paper
• Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells

  2007cited by this paper
• MicroRNAs and immunity: tiny players in a big field.

  2007cited by this paper
• Let-7 Prevents Early Cancer Progression by Suppressing Expression of the Embryonic Gene HMGA2

  2007cited by this paper
• Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR

  2007cited by this paper
• Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.

  2007influential reference
• New insight into BRAF mutations in cancer.

  2007influential reference

• Therapeutic Strategies for Drug-resistant Melanoma and Their Clinical Implications

  2025cites this paper
• Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers

  2023cites this paper
• Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy.

  2023cites this paper
• Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management

  2022cites this paper
• Primary Squamous Cell Carcinoma of the Thyroid Gland

  2022cites this paper
• Head and neck surgical oncology

  2022cites this paper
• Papillary Thyroid Carcinoma: Current Position in Epidemiology, Genomics, and Classification.

  2022cites this paper
• BRAF Mutations in Papillary Thyroid Carcinoma: A Genomic Approach Using Probe-Based DNA Capture for Next-Generation Sequencing.

  2022cites this paper
• Capturing ctDNA from Unaltered Stationary and Flowing Plasma with dCas9.

  2022cites this paper
• Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy—Who Is at the Greatest Risk?

  2021cites this paper
• Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma

  2020cites this paper
• Cellular and Molecular biology in oesophageal cancer

  2020cites this paper
• Monitoring Cellular Immune Responses in Cancer Therapy

  2020cites this paper
• Thyroid squamous cell carcinoma: a unique type of cancer in World Health Organization classification.

  2020cites this paper
• Overview of established and emerging immunohistochemical biomarkers and their role in correlative studies in MRI

  2020cites this paper
• Quantitative Interrogation of the Human Kinome Perturbed by Two BRAF Inhibitors.

  2019cites this paper
• Cellular and Molecular Biology of Esophageal Cancer

  2019cites this paper
• All-trans Retinoic Acid Overcomes Acquired Resistance to PLX4032 via Inhibition of PIN1 in Melanoma Cells

  2019cites this paper
• AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status

  2018cites this paper
• IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.

  2018cites this paper
• Immunohistochemical Detection of BRAF in Iraqi Women with Different Breast Tumors

  2017cites this paper
• Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases

  2017cites this paper
• Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

  2017cites this paper
• Novel FAM134B mutations and their clinicopathological significance in colorectal cancer

  2017cites this paper
• BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody

  2016cites this paper
• Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1 , epidermal growth factor receptor , and p 53 expression

  2016cites this paper
• Effect of SNX-2112 on proliferation of esophageal cancer cells via regulation of excision repair cross-complementing 1, epidermal growth factor receptor, and p53 expression.

  2016cites this paper
• Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas

  2016cites this paper
• Two is better than one; toward a rational design of combinatorial therapy.

  2016cites this paper
• Lack of BRAF-V600E Mutation in Papillary Tumor of the Pineal Region.

  2015cites this paper
• Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.

  2015cites this paper
• Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.

  2015cites this paper
• MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.

  2015cites this paper
• Cellular and Molecular Biology of Esophageal Cancer

  2015cites this paper
• Evaluation of Small Biopsy Material in Patients with Multiple and Secondary Tumors

  2015cites this paper
• BRAF inhibitors: From the laboratory to clinical trials.

  2014cites this paper
• Escherichia colistrains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia

  2014cites this paper